Clinical Trials Browser

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02924766 2020-07-20

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Phase 1 Completed

34 enrolled

Genitourinary

Prostatic Neoplasms

NCT00749502 2013-07-25

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Phase 1 Completed

113 enrolled

GenitourinaryGynecologicLymphoidOther hematologic neoplasm

Adnexal Diseases, Endocrine System Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Genital Diseases, Male, Genital Neoplasms, Female, Genital Neoplasms, Male, Gonadal Disorders, Neoplasms, Ovarian Diseases, Ovarian Neoplasms, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

Clinical Trials

MAGNITUDE

AMPLITUDE

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

QUEST

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Galahad

PAVO

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)